Topical anti-Staphylococcus bacteriophage therapy
Phase 2Small molecule
Topical anti-Staphylococcus bacteriophage therapy is one of 36 small molecule programs targeting Diabetic Foot. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
35
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
49 competitors in Diabetic Foot
#DrugCompanyPhaseTrials
1Desferal
Jazz PharmaceuticalsApproved
Remodulin
United TherapeuticsApproved
Vancocin
HHikma Pharmaceuticals LLC
Approved
Januvia
ZZydus Therapeutics Inc.
Approved
Caverject
VViatris Specialty LLC
Approved
Sporanox
SSebela Pharmaceuticals Development LLC
Approved
Nitrostat
VViatris Specialty LLC
Approved
Inomax
MMallinckrodt
Approved
Tobrex
VViatris Specialty LLC
Approved
Acetadote
AArbor Pharmaceuticals, Inc.
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Diabetic Foot1 trial
Standard Treatment Associated With Phage Therapy Versus Placebo for Diabetic Foot Ulcers Infected by S. Aureus
Not yet recruiting·—·Phase 1/2·NCT02664740·60 enrolled
Sources
References
- [1]
- [2]
- [3]
- [4]
Details